NCT05814835 - First in Human Study of 68Ga/64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors | Biotech Hunter

Enrollment

14

Participants

Timeline

Start Date

December 7, 2022

Primary Completion Date

November 30, 2023

Study Completion Date

December 18, 2023

Conditions

Malignant Solid Tumors

Interventions

DRUG

2-4 mCi 68Ga/64Cu-FAPI-XT117

68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 2-4 mCi 68Ga/64Cu-FAPI-XT117 injection.

DRUG

4-6 mCi 68Ga/64Cu-FAPI-XT117

68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 4-6 mCi 68Ga/64Cu-FAPI-XT117 injection.

DRUG

6-8 mCi 68Ga/64Cu-FAPI-XT117

68Ga/64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 6-8 mCi 68Ga/64Cu-FAPI-XT117 injection.

Trial Locations (1)

100023

the First Medical Center, Chinese PLA General Hospital, Beijing